Matinas Biopharma Holdings Inc. Common Stock (MTNB)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power, honest accounting, and a margin of safety. Matinas is a testing-stage biopharmaceutical company with no revenue in recent filed figures. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $1.3 million and diluted EPS of -$0.21; in FY2025 it lost $10.3 million, or -$2.00 per diluted share; in FY2024 it lost $24.3 million, or -$4.98 per diluted share. The only filed revenue shown is $1.1 million in FY2023, which is not a meaningful commercial base. At the 2026-10-13 close of $2.50, market cap was $3.8 million. FairStock's calculations show P/E -2.17, P/B 8.93, ROE -141.24%, ROCE -56.17%, free cash flow -$6.4 million, FCF yield -168.0%, Piotroski 2/9, and Altman Z-score -86.47. Debt/equity is 0.00, so there is no leverage, but the cash burn is severe. The LNC platform and MAT2203 in Phase 3 offer optionality, yet I cannot see a durable competitive moat in the numbers. With two employees and no product revenue, the value depends on clinical and regulatory outcomes and repeated financing. The Lynch category is none because it has lost money in each of the last four years. Graham would want assets or earnings; Buffett would want a moat. This fails both tests today.

In plain English: Matinas is a very small drug company trying to make an easier-to-take version of an antifungal medicine. It has no real sales and has been losing money, so the business looks financially weak. At $2.50 a share, the price does not look supported by current profits or sales and seems expensive for a company this small and unprofitable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer